Health Canada Issues Recall of Zoetis` Clavamox Drops
Eli Lilly ($LLY) stirred up some rough waters earlier this year, with lagging sales for older meds and a 2015 forecast that fell short of analysts' expectations. But CEO John Lechleiter predicted good things ahead--and now it looks as if Lilly has reached calmer waters.
What's with all the M&A rumors floating around in the animal health world? Just look at Zoetis' ($ZTS) Apoquel and it's clear why Big Pharma names are keen to bolster their positions in the space.
Healthcare conglomerate Bayer (BAY) is not in talks to acquire animal health company Zoetis (GZTS), it told an analyst recently, a week after widespread reports linked it and Canadian drugmaker Valeant Pharmaceuticals International, Inc. (VRX) to forthcoming bids for the firm.
Whether animal health leader Zoetis ($ZTS) receives any more buyout offers after Valeant's ($VRX) reported approach remains to be seen. But if it does, Bayer's leaders insist a competing bid won't be coming from them.
Canada`s Valeant approaches to buy Zoetis: WSJ
Bayer Animal Health plant closing next week leaving 120 without jobs
Zoetis knocks off 165 NJ jobs in Ackman-forced cost squeeze
Pfizer Spinoff Zoetis Chops 165 HQ Jobs as Part of Global Restructuring
Who`s The Next Big Pharma Acquisition?